ST.
PAUL, Minn., Dec. 18,
2024 /PRNewswire/ -- ScaleReady, in collaboration
with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ:
TECH) and CellReady, today announced that Moonlight Bio has been
awarded a G-Rex® Grant. Moonlight Bio's G-Rex® Grant will expedite
process development and IND-enabling studies of their lead CAR T
cell therapy for the treatment of solid tumors.
"We are grateful to receive a G-Rex Grant to support the
advancement of our lead CAR T asset into the clinic in a platform
that is cost effective and scalable. This mechanism is a creative
solution that provides access to expertise and a highly efficient
manufacturing platform to biotechnology companies in a way that
saves significant time and money," said Dr. Jordan Jarjour, Chief Scientific Officer at
Moonlight Bio.
"I'm confident that Moonlight Bio will quickly find out that
ScaleReady's expertise and the G-Rex Grant Program will preserve
the two most precious commodities for any cell therapy entity, time
and money," said John Wilson, CEO of
Wilson Wolf Manufacturing and co-inventor of G-Rex.
Moonlight Bio's technology is based on a recent
article published in Nature from the labs of two of their
scientific co-founders, Dr. Kole
Roybal and Dr. Jaehyuk Choi,
that describes a unique approach to enhance engineered T cell
therapies by co-opting mutations that naturally occur in T cell
malignancies (PMID: 38326614). By screening dozens of
mutations from T cell neoplasms, their results indicate that
exploiting naturally occurring mutations represents a promising
approach to discover how solutions derived from the selective
process of cancer evolution can improve T cell therapies.
As part of the G-Rex Grant, ScaleReady will provide Moonlight
Bio access to a commercially viable CAR T manufacturing platform.
The G-Rex Grant may also be used to defray the cost associated with
validation runs to support the IND-enabling studies for Moonlight's
lead CAR T asset. Additionally, Moonlight Bio will get access
to Bio-Techne's new closed system reagent solutions,
ProPak™ and GMP Cytokines for simplification of cytokine
delivery. Finally, Moonlight Bio will have the option to receive a
complimentary analysis of their master manufacturing batch records
by CellReady, the world's first and only G-Rex centric contract
development and manufacturing organization, to ensure commercial
viability of the manufacturing process.
ScaleReady's G-Rex Grant Program is a $20M initiative to advance the state of cell and
gene-modified cell therapy (CGT) development and manufacturing by
awarding individual Grant Awards worth up to $300,000. G-Rex Grant Recipients also gain
access to exclusive support from ScaleReady's growing consortium of
G-Rex Grant Partners who bring best-in-class tools and technologies
as well as unparalleled knowledge and expertise in the areas of
cGMP manufacturing, quality and regulatory affairs, CGT business
operations, and more.
For more information about the G-Rex® Grant Program, please
contact info@scaleready.com.
About ScaleReady
ScaleReady provides the field of
cell and gene-modified cell therapy (CGT) with a G-Rex centric
manufacturing platform that enables the world's most practical,
flexible, scalable, and affordable CGT drug product development and
manufacturing.
The G-Rex manufacturing platform is currently used by a rapidly
growing list of over 800 organizations and is producing drug
products for approximately 50% of CGT clinical trials as well as 5
commercially approved CGT drugs.
CGT entities relying on the breadth and scope of ScaleReady's
expertise can expect to save years of time and millions of dollars
on the path to CGT commercialization.
For more information about the ScaleReady G-Rex® Grant Program,
please contact info@scaleready.com.
About Moonlight Bio, Inc.
Moonlight Bio, Inc. is a
preclinical-stage biotechnology company based in Seattle, WA aiming to develop potency enhanced
T cell therapies that provide new hope for patients suffering from
cancer. Moonlight's core technologies were illuminated by nature
itself and are designed to confront the disappointing reality that
therapies for solid tumors are simply not potent enough to generate
the deep and durable responses that patients urgently need. To
learn more, connect with Moonlight Bio on LinkedIn and visit us at
http://www.moonlightbio.us/.
About Wilson Wolf Manufacturing
Wilson Wolf (www.wilsonwolf.com) is dedicated to
simplifying cell and gene-modified cell (CGT) therapy research,
process development, and manufacturing. This is being
accomplished through its scalable G-Rex technology, which is used
throughout the world in CGT applications ranging from basic
research to commercial drug production.
Wilson Wolf's mission is to
create hope for cancer patients, one G-Rex® device at a time.
About Bio-Techne Corporation
Bio-Techne Corporation
(NASDAQ: TECH) is a global life sciences company providing
innovative tools and bioactive reagents for the research and
clinical diagnostic communities. Bio-Techne, in partnership with
Wilson Wolf, is creating products
such as media and cytokines that are specifically tailored to
G-Rex® Bioreactors, including right-sized reagent quantities in
containers that are tailored to high throughput closed-system
manufacturing. For more information on Bio-Techne and its brands,
please visit http://www.bio-techne.com or follow the Company on
social media at Facebook, LinkedIn, Twitter or YouTube.
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice
President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
About CellReady LLC
CellReady is the world's first and
only G-Rex centric contract development and manufacturing
organization (CDMO) specializing in G-Rex based cell and
gene-modified cell therapy development and manufacturing. The
company offers a wide range of services to support the development
and commercialization of these therapies.
CellReady's mission is to create hope for cancer patients, one
G-Rex® process at a time.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/scaleready-awards-a-g-rex-grant-to-moonlight-bio-302334680.html
SOURCE Bio-Techne Corporation